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Background: Age-related macular degeneration (AMD) is the leading cause of central vision loss in older adults.
Anti-retinal autoantibodies (AAbs) have been found in individuals with AMD. The goal of the study was to
determine the AAb specificity in different stages of AMD, and determine whether there is a prevalent AAb signature.
Methods: Sera of 134 participants in the Age-related Eye Disease Study were analyzed for anti-retinal AAbs by western
blotting. The subjects were classified by diagnostic subgroups based upon their clinical classification: No AMD,
Intermediate AMD, and Late AMD - geographic atrophy (GA) and Late AMD - neovascular (NV).
Results: The presence of anti-retinal AAb was detected in 58% patients with Intermediate and Late AMD, and 54% of
those with no AMD. AAbs bound to fifteen different retinal antigens. Most individuals had 1 specific AAbs (67%), with
the remainder having 2 to 4 different AAbs. Over 40% of patients with Intermediate AMD, and 46% of those with GA
had anti-enolase AAbs, compared with 29% of individuals with NV and 29% with no AMD. Different AAbs signatures
related to NV as compared to GA and/or Intermediate AMD were distinguished. Anti-40-kDa (10%) and 42-kDa (16%)
autoantibodies were associated with Intermediate AMD, while anti-30-kDa AAbs (23%) were primarily present in GA.
Anti-32-kDa (12%), 35-kDa (21%), and 60-kDa (8%) AAbs were more frequent in NV AMD.
Conclusions: A unique AAb pattern for each of the disease subgroups was present when AMD progressed from the
intermediate to the late forms of severity. Differences in the frequency of specific AAbs between AMD subgroups
suggested that they may participate in pathogenicity of AMD. Further studies are necessary to confirm these
observations in the larger cohort and individual AMD patients over time.
Keywords: Age-related macular degeneration, AREDS, Autoantibodies, Enolase, Antibody signature, Biomarker, Retina,
Macula, Smoking, ArthritisBackground
Age-related macular degeneration (AMD) is the leading
cause of central vision loss in older adults [1,2]. The
etiology of AMD appears to be diverse, including age,
genetic predisposition, diet, smoking, and other environ-
mental risk factors [3,4]. Considerable evidence supports
a strong role for local inflammation including the accu-
mulation of macrophages, lymphocytes, and mast cells
found in association with both forms of late AMD: geo-
graphic atrophy (GA) and neovascular AMD [5-9]. Large* Correspondence: adamusg@ohsu.edu
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unless otherwise stated.drusen deposits in the macula (intermediate AMD) gen-
erally precede development of the late stages of AMD.
The composition of these immunologically active dru-
sen deposits includes proteins, lipids, complement, and
other substances that may act as triggers for immune
responses in the eye [7,10]. In addition, the activation of
complement factors and secondary mediators of in-
flammation such as cytokines and chemokines has been
demonstrated in serum from AMD patients [3,11-13].
These findings suggest the possible involvement of IL-22
and IL-17 in the inflammation that contributes to patho-
genicity of AMD, and C5a may be one of the factors
contributing to the elevated serum levels in AMD pa-
tients [14,15].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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retinal autoantibodies (AAbs) in association with AMD,
although it is unclear whether such AAbs play an active
role in the etiology of disease or if they are generated in a
response to retinal injury from the underlying disease pro-
cesses [16-21]. It is possible that both the generation of
AAbs as well as the activation of complement could be
responses to retinal damage/degradation [21-23]. Ne-
vertheless, recent studies have demonstrated the presence
of various AAbs in individuals with AMD, including
anti-aldolase C, anti-pyruvate kinase isoform M2, anti-
retinaldehyde binding protein 1, and anti-retinol binding
protein 3 [16,17,20,24]. The detection of AAbs could
conceivably be important in subtyping the disease with
specific antibody signatures (multiple antibody arrays),
eventually helping define pathogenesis and optimum the-
rapy. The goal of our study was to determine the AAb
specificity in different stages of AMD, and prevalence of
AAb signatures in relation to AMD severity.
Methods
Patients
Sera of 134 participants in the Age-related Eye Disease
Study (AREDS) were selected for analysis. Detailed de-
mographic and clinical information was obtained before
blood samples were collected. Informed consent to par-
ticipate in the Age-related Eye Disease Study was ob-
tained from all participants. The study was approved by
the Oregon Health and Science University Institutional
Review Board (IRB#2421) and was conformed to the
provisions of the Declaration of Helsinki.
All samples were stored at −80°C prior to use. Demo-
graphic characteristics of the study population are shown
in Table 1. The study group consisted of 66 males and 68
females. The serum samples represented different disease
stages reflecting AMD severity. The subjects were classified
by diagnostic subgroups based upon their AREDS classifi-
cation at the time of blood collection: 1. No AMD controls
(N = 26) - no drusen or small drusen (<63 μm diameter) in
the worse eye; 2. Intermediate AMD (N= 41) - large
drusen (125 μm or greater) in one or both eyes; and 3. Late
AMD (N = 67) – either geographic atrophy (N = 28), neo-
vascular AMD (n = 33); or both neovascular AMD andTable 1 Association of autoantibodies against retinal protein
Stage of AMD Number of subjects
No AMD (Control group) None or small drusen 26
Intermediate AMD Large drusen in one or both
eyes (drusen 125 μm or greater)
41
Late AMD Total (NV, GA, and Both) 67
Geographic atrophy 28
Neovascular AMD 33
Both: neovascular and geographic atrophy 6geographic atrophy (N= 6). These AMD categories are
illustrated in fundus photographs presented in Figure 1.
Testing for anti-retinal autoantibodies
Western blotting was performed using retinal proteins
extracted from a donor human retina with 1% octyl glu-
coside in phosphate/saline buffer (PBS), pH 7.2, and se-
parated by gel electrophoresis as described previously
[25]. Briefly, after separation by SDS-gel electrophoresis
on a 10% gel (Bio-Rad) the proteins were transferred to
an Immobilon membrane (Millipore). Next, individual
strips containing retinal proteins were blocked with a
buffer containing 10% normal goat serum and 1% bovine
serum albumin in PBS for one hour followed by the in-
cubation with 1:100 diluted serum for 1 hour. Secondary
anti-human IgG (H and L chain) antibodies conjugated
to alkaline phosphatase (Invitrogen) were added for
another hour. Then color reaction was developed by ad-
ding the phosphatase substrate until dark bands appeared
in positive controls (anti-recoverin and anti-enolase anti-
bodies). A negative control strip was not incubated with
primary antibodies.
Statistical analysis
GraphPad Prism software (San Diego, CA) was used for
statistical analysis. Statistical analyses were performed
using one-way analysis of variance or Student’s t test.
P <0.05 was considered as statistically significant. Fisher’s
exact test was employed to evaluate differences in auto-
antibody frequency between groups. Differences between
groups were evaluated using one-way ANOVA.
Results
Prevalence of autoantibodies in AMD subgroups
Sera of the 134 AREDS participants were analyzed for
anti-retinal AAbs by western blotting using human re-
tinal proteins. Table 1 shows the demographic charac-
teristics and anti-retinal seropositivity for each AMD
subgroup. Overall, the levels of AAbs were fairly constant
(49% - 67%) over the severity spectrum of the disease
(Table 1, Figure 2A). However, there were specific AAbs
associated with different severity stages (see below). AAbs
in females and males showed a similar tendency of almosts with different stages of AMD
Average age Female/Male Presence of AAbs seropositive/group
68 15/11 14/26 (54%)
69 25/16 26/41 (63%)
73 33/34 38/67 (57%)
74 9/19 18/28 (64%)
72 19/14 16/33 (49%)
73 5/1 4/6 (67%)
Figure 1 Fundus photographs illustrating subgroups of AREDS patients in the study. (A) No AMD; (B). Intermediate AMD showing large
drusen in the macula; (C) Late AMD - geographic atrophy; (D) Late AMD - neovascular AMD; (E) late AMD – both geographic atrophy and
neovascular AMD. Stars indicate the affected areas.
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nor difference in incidence within severity disease stages
(Figure 2B). The relatively persistent rate of anti-retinal
AAbs across all subgroups suggests that autoantibodies
were likely generated during the early stage of maculo-
pathy or were a part of the aging process since the patients
and controls were of similar age [26].
Autoantibody signatures
AMD and age-control autoantibodies bound to 15 dif-
ferent retinal antigens were identified here by their mo-
lecular weight. Sixty nine percent of sera reacted with a
singular antigen while the remaining 31% reacted with 2
to 4 different retinal antigens. In the AMD subgroups,
51% (21/41) of patients with intermediate AMD, 32%
(9/28) of patients with late AMD-GA, and 30% (10/33)
of patients with late AMD-NV were seropositive for 1retinal antigen. In contrast, 19% (5/26) of control sera
were positive for the singular AAb. Figure 3 shows the
distribution of anti-retinal AAbs in each of the severity
stages. Different AAb signatures related to intermediate
AMD, as compared to late AMD (GA and/or NV) were
distinguished, and there was a unique AAb pattern for
each of the disease subgroups that changed when pro-
gressing from the intermediate to the late forms of
AMD. The comparison of subgroups showed significant
differences in the AAbs occurrence between AMD
groups (p < 0.0001, one way ANOVA).
We evaluated the occurrence of specific antibodies for
each AMD subgroup. We do not provide the identity of
the targeted antigens (except enolase, which is a 46-kDa
protein) because of insufficient serum amounts for full
identification of these retinal antigens. Figure 3 illus-
trates AAb occurrence in each subgroup and Table 2
Figure 2 Incidence of anti-retinal autoantibodies in patients
with AMD and age-matched unaffected control subjects.
(A) Seropositive total subjects with AMD divided into the AMD
subgroups and controls, and in (B) Seropositive females and males
with AMD and controls. Groups: control group (no AMD), intermediate
AMD, late AMD – geographic atrophy (GA), late AMD – neovascular
(NV) AMD.
Figure 3 Anti-retinal autoantibodies in different stages of AMD.
Distribution of anti-retinal autoantibodies against 15 different retinal
proteins identified by molecular weight in the 4 study groups of pa-
tients: control group (no AMD), intermediate AMD, late AMD - geo-
graphic atrophy, and late AMD - neovascular AMD. Bars show the
percent of positive AAbs for each antigen; arrows point at unique
antigens for each AMD group.
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stages. We found that anti-40-kDa (10%) and 42-kDa
(16%) autoantibodies were associated more commonly
with intermediate AMD, while anti-30-kDa AAbs (23%)
were primarily present in late AMD-GA. AAbs against
32-kDa (13%), 35-kDa (21%), and 60-kDa (8%) proteins
were more frequent in individuals with late AMD-NV.
Over 40% of patients with intermediate AMD, and 46%
of those with late AMD-GA had ~1.5-fold higher rate of
anti-enolase (anti-46-kDa) AAbs, compared with 29% of
individuals with late AMD-NV and 28% of controls.
A similar tendency of decreasing serum AAbs in the late
stages of AMD was observed for anti-42-kDa reactivity
showing a 2-fold decline from 16% for intermediate AMD
to 8% in late AMD-NV. Also, anti-42-kDa AAbs were
4-fold higher in the intermediate AMD group than in no
AMD controls, in which only 4% of those AAbs werepresent. In contrast, anti-35-kDa AAbs showed ~7-fold
increase in the late AMD-NV group as compared with the
intermediate AMD group. The comparison of those 3
Table 2 Seropositivity associated with different stages of




for a single antigen
Unique
antigens*



















Late AMD - Both
GA + NV
4/6 (67%) 4/6 (67%) Not
determined
*Unique retinal antigens are presented as a percentage of total recognized
antigens present within a group.Antigens are identified by molecular
weight (K = 1000).
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p = 0.0008). Figure 4 shows an increased level of anti-40-
kDa, anti-42-Da, and anti-68-kDa AAbs in the interme-
diate AMD group, while anti-30-kDa and anti-35-kDa
AAbs were elevated in late AMD. Together, these resultsFigure 4 Trends in AAbs associations between intermediate and late
weight (30-kDa, 35-kDa, 40-kDa, 42-kDa, and 68-kDa) have a tendency to decre
as others to increase (anti-30-kDa and anti-35-kDa) that could potentially be usuggest that some of those AAbs may potentially be con-
sidered as biomarkers for different stages of AMD.Association of autoantibodies with smoking and arthritis
in AMD
Genetic and environmental factors play a role as indica-
tors of disease outcome in AMD, including smoking and
arthritis [4,27]. Smoking has been shown to predispose to
the development of several AAbs [28,29]. To determine
whether current tobacco smokers, ex-smokers, and ever-
smokers of both sexes with AMD have anti-retinal AAbs
we analyzed antibody presence in three groups: 1) ever-
smokers (n = 41), 2) current smokers (n = 8), or 3) former
smokers (n = 59). Our results show that women ≤65 years
that never smoked had significantly higher levels of AAbs
than did men of the same age and a history of cigarette
smoking. Gender differences remained in ex-smokers but
with opposite trends in all stages of AMD. Figure 5A
shows that never smoking women with intermediate
AMD and AMD-GA had ~3 times higher prevalence of
AAbs than never smoking men (Figure 5B). In contrast,
current or ever male smokers had higher incidence of
serum AAbs than women. Seropositivity in arthritis and
AMD was found in 20/58 (35%) women and 11/50 (20%)
men. Female with intermediate AMD had 4 times
greater incidence of AAbs than men, and in contrast, men
with NV had 2-fold greater frequency of anti-retinalAMD. Five anti-retinal AAbs designated by their target antigen molecular
ase in advance stages of AMD (anti-40-kDa, anti-42-kDa, and anti-68-kDa)
sed as disease biomarkers.
Figure 5 Relationship of anti-retinal autoantibodies in different stages of AMD with smoking and arthritis. (A) Prevalence of anti-retinal
autoantibodies in men and women who never smoked, are current smokers, or who stopped smoking in AMD and control subjects. High anti-retinal
seropositivity is observed in never smoking females that dropped 2 folds in ever smoker female patients. In contrast, smoking or discontinuation of
smoking is associated with an increased frequency of AAbs in men regardless of the stage of disease. Never = never smoking female/male; Current =
currently smoking female/male; Ever = former smoking female/male. (B) Differences in anti-retinal autoantibody association in female and male with
AMD and arthritis and compared to the age-matched unaffected controls. Bars represent a percent of seropositive subjects in each subgroup. Note
that female with intermediate AMD had 4 times more AAbs than men, in contrast men with late AMD-NV had 2 times higher frequency of anti-retinal
antibodies. Horizontal lines show statistical significance between groups, p < 0.05 (One-way analysis of variance, Bonferroni’s multiple comparison test).
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statistically significant but the sample size was small.Discussion
The etiology of AMD is complex and includes genetic
risk factors, environmental factors, age, and immune
and autoimmune causes [30]. Several potential immune
mediators are known to play a role in the pathogenic
process of AMD, such as infiltration of macrophages,
presence of cytokines/chemokines, T-lymphocytes, as
well as formation of autoantibodies [1,5]. Our studies
demonstrated a complex pattern of AAbs against several
retinal proteins in individuals with AMD with fairly con-
stant presence over the severity spectrum of the disease.
We also identified AAbs that could be markers of
disease activity (Figures 3 and 4). We believe that early
generation of anti-retinal AAbs may create an environ-
ment that promotes cell loss, angiogenesis, and progres-
sion to late stages of AMD [31]. Since in autoimmune
diseases, the immune response is itself part of the dis-
ease process, it is possible that the consistent presence
of AAbs suggests their contribution to pathogenicprocesses through the availability of the antigens from
degenerating retina.
Previously published studies showed the association of
AAbs with AMD, suggesting a contribution of the immune
system to pathogenicity of the disease [7,17,19,32,33]. Se-
veral autoantibodies to retinal antigens have been identi-
fied, including anti-glial fibrillary acidic protein (GFAP),
anti-α-enolase, and anti-carboxyethylpyrrole (CEP), an
oxidized component of drusen [17,32,34,35]. GFAP is a
52-kDa antigen, the main intermediate filament protein in
mature astrocytes, that was targeted in 44% of the AMD
patients’ population studied [17]; however, we have not
found AAbs against 52-kDa antigen in a measurable level
in our cohort. The study examined approximately the
same number of patients as our study reported anti-
enolase AAbs in 67% of the AMD patients, which are
similar to our findings [17]. Other studies showed that
AAbs in individuals with neovascular AMD recognized
retinol-binding protein 3 (RBP3, 120-kDa), retinol-binding
protein 1 (RLBP1, 36-kDa) and aldolase C (39-kDa) [20].
RBP3 is an essential protein for the exchange of retinoid
between the RPE and photoreceptors and their survival
because it prevents the potentially cytotoxic effects of
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33% (6 of 18) of patients with AMD and also in 24% (11
of 45) of patients with Macular Telangiectasia Type 2 [36].
The authors suggested that the existence of mutual AAbs
in MacTel-2 and AMD shared some common etiologic or
pathogenic mechanisms for both conditions. RBP3, also
known as interphotoreceptor retinoid binding protein
(IRBP), is a unique protein to the photoreceptor cells in
the retina, which has been found to be highly pathogenic
in animals. Immunization of animals with IRBP induced
an intraocular inflammatory disease that is primarily me-
diated by T cells but anti-IRBP antibodies are also present,
suggesting their role in inflammation. Moreover, anti-
IRBP autoantibodies and T cell have been also found in
patients with uveitis, retinitis pigmentosa, and progressive
rod-cone degeneration [37-41]. Cellular retinaldehyde-
binding protein (CRALBP), transcribed from the RLBP1
gene, is a 36-kDa protein found in the RPE and in retinal
Müller cells [42]. Both elevated seroreactivity to RBP3 and
RLBP1 in AMD patients suggests that the inflammation,
in particular, autoimmunity, is strongly associated with the
pathogenesis of the disease [11]. In our cohort, a 35-kDa
antigen is likely to be CRALBP although its identity wasn’t
confirmed (due to insufficient quantity of samples) if con-
firmed, these AAbs would be found to be 2 times more
frequent in individuals with AMD than in controls. None-
theless, anti-CRALBP AAbs have been found in uveitis,
showing 54% seropositivity in patients with uveitis com-
pared to 17% in normal subjects [43], they were also
detected in patients with cancer-associated retinopathy,
CAR (Adamus, unpublished information). Altogether,
these findings indicated that anti-IRBP and anti-CRALBP
AAbs are not highly specific for AMD individuals.
It is not surprising to find autoantibodies against
α-enolase (46-kDa), aldolase C (40-kDa), and pyruvate
kinase M2 (60-62-kDa) that previously were found in
both neovascular and geographic atrophy AMD [17,20].
These key enzymes of the glycolytic pathway may promote
autoimmunity by acting as autoantigens. α-Enolase, also
called non-neuronal enolase, belongs to a family of glyco-
lytic enzymes but also has other cellular functions related
to its subcellular localizations that are distinct from its
well-established activity in glycolysis [44-46]. Furthermore,
differential expression of α-enolase and presence of
specific AAbs have been related to several pathologies,
such as cancer, Alzheimer’s disease, autoimmune diseases,
and rheumatoid arthritis, among others. Antibodies
against α-enolase have been strongly associated with CAR
[25,47-49]. Recently, we showed that AAbs against anti-
glycolytic enzymes were highly associated with CAR and
gynecological cancers [50]. In vitro and in vivo studies
showed that anti-enolase AAbs have pathogenic potential
in killing retinal cells [51-53]. Generation of AAbs against
enolase and other anti-glycolytic enzymes may be anormal process since they can be found in healthy individ-
uals. However, it is possible that excessive production of
such autoantibodies can be generated as a consequence of
enolase uptake by antigen-presenting cells and subsequent
B cell activation, can potentially initiate a tissue injury as a
result of immune complex deposition, or an induction of
apoptosis leading to the death of retinal cells.
Autoantibodies against CEP, an adduct that develops
from an oxidation fragment of docosahexaenoic acid
(DHA), are present in plasma and are more abundant in
AMD than in controls, suggesting their potential as a bio-
marker for AMD [32]. Animal studies showed that mice
immunized with CEP-modified mouse serum albumin
generated anti-CEP antibodies that consequently induced
AMD-like lesions in the outer retina, suggesting that auto-
immunity was associated with the initiation or progression
of AMD [34]. CEP is typically present in photoreceptor
rod outer segments, and RPE in the mouse retina, and its
reactivity is more intense in photoreceptors of human
AMD retina than healthy retina [32].
In AREDS, persons with either intermediate drusen,
extensive small drusen, or the pigment abnormalities asso-
ciated with AMD were more likely to be female, and more
likely to have a history of arthritis [4]. This might suggest
an association with chronic inflammatory disease. We
found that women with arthritis and intermediate AMD
had significantly greater incidence of AAbs than men, sug-
gesting possible sex hormone effects. Changes in sex hor-
mones mainly influence onset of rheumatoid arthritis in
older individuals of both sexes [54]. Lower levels of testos-
terone in men, and early menopause in women, may be
signs of premature aging, putting them at greater risk of
developing diseases and thus antibodies.
Epidemiologic evidence indicates that smoking cigarettes
results in an increased risk of AMD [27,55]. Smokers of
both sexes have an increased risk of developing seroposi-
tive rheumatoid arthritis (RA) [56]. For example, in RA,
the presence of anti-citrullinated protein antibodies has
been described to be specifically associated with smoking.
Also, smoking has also been shown to be associated with
AAbs in various other autoimmune diseases, such as anti-
dsDNA in systemic lupus erythematosus, and anti-Jo1 in
idiopathic inflammatory myopathy. There is evidence that
citrullinated α-enolase is present in the lungs of smokers
[57]. However, the precise mechanisms whereby smoking
may trigger immunity to citrullinated α-enolase remain to
be elucidated. Gender differences in our cohort were
evident in AAb frequencies in never, current, and ever
smokers with somewhat surprising results. Women who
had never smoked presented with a higher prevalence of
anti-retinal AAbs than women who were former smokers,
which suggests a possible influence of sex hormones
(e.g., estrogens). Estrogen strongly stimulate the immune
response [58] and also can induce AAb levels in persons
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AMD were protected from developing anti-retinal AAbs,
in contrast to ex-smokers who had higher prevalence of
AAbs. Testosterone plays an important role in the mo-
dulation of inflammatory processes and may neutralize the
adverse changes of immune response [60]. Testosterone is
known to promote apoptosis of Th2 cells and develop-
ment of the Th1 phenotype of cytokine production, which
results in suppression of humoral immune response. A fall
of testosterone concentration in aging men can influence
oxidative modification and the immune response, which is
important in the pathogenesis of atherosclerosis.
Conclusions
The role of AAbs in the induction or acceleration of ret-
inal deterioration is uncertain. Our studies showed that
AAbs against retinal proteins are apparently different in
various AMD severity subgroups. However, the differences
in frequency of specific AAbs between AMD subgroups
may suggest that they participate in pathogenicity of
AMD. Also, different AAbs co-exist in individual patients,
possibly creating antibody signatures specific to each stage
of AMD. If confirmed by other studies, these elevated
levels of specific antibodies may be a useful predictor or
biomarker of AMD progression from intermediate to late
AMD. On the other hand, it is reasonable to suggest that
the high frequency of AAbs in persons with AMD as well
as healthy individuals is a consequence of this progressive
‘aging’ of the immune system. However, pathogenic AAbs
that can be detected in peripheral blood years before the
destruction of retinal cells may lead to obvious clinical
symptoms. Regardless of their role, AAbs may be useful as
biomarkers and we presented a few possible candidates
for each stage of AMD progression even though we could
not provide the identity of the targeted antigens (except
enolase). This was a limitation of this research because
insufficient serum amounts did not allow for full identifi-
cation of these retinal antigens. Further studies are neces-
sary to confirm our results in the larger cohort of patients
with AMD, and also to examine individual patients over
the progression of their macular disease, and to identify
the targeted antigens.
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